CN101679412A - 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类 - Google Patents

作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类 Download PDF

Info

Publication number
CN101679412A
CN101679412A CN200780053087A CN200780053087A CN101679412A CN 101679412 A CN101679412 A CN 101679412A CN 200780053087 A CN200780053087 A CN 200780053087A CN 200780053087 A CN200780053087 A CN 200780053087A CN 101679412 A CN101679412 A CN 101679412A
Authority
CN
China
Prior art keywords
alkyl
compound
salt
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780053087A
Other languages
English (en)
Chinese (zh)
Inventor
A·拉夫坦
荣亚静
何国勤
M·奥尔迈耶
O·迪勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LETOURNEAU JEFFREY CO Ltd
Original Assignee
LETOURNEAU JEFFREY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LETOURNEAU JEFFREY CO Ltd filed Critical LETOURNEAU JEFFREY CO Ltd
Publication of CN101679412A publication Critical patent/CN101679412A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200780053087A 2007-05-23 2007-05-23 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类 Pending CN101679412A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/069530 WO2008143674A1 (en) 2007-05-23 2007-05-23 Purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Publications (1)

Publication Number Publication Date
CN101679412A true CN101679412A (zh) 2010-03-24

Family

ID=39262569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780053087A Pending CN101679412A (zh) 2007-05-23 2007-05-23 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类

Country Status (6)

Country Link
EP (1) EP2152708A1 (ja)
JP (1) JP2010527999A (ja)
CN (1) CN101679412A (ja)
CA (1) CA2686485A1 (ja)
MX (1) MX2009012612A (ja)
WO (1) WO2008143674A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689637A (zh) * 2018-09-13 2021-04-20 橘生药品工业株式会社 咪唑并吡啶酮化合物
WO2021104277A1 (zh) * 2019-11-25 2021-06-03 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物
RU2796163C1 (ru) * 2019-11-25 2023-05-17 Цзай Лаб (Шанхай) Ко., Лтд Пиримидоимидазольные соединения, применяемые в качестве ингибиторов днк-pk

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2009062059A2 (en) * 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
RU2553681C2 (ru) 2009-10-29 2015-06-20 Вектура Лимитед N-содержащие гетероарильные производные в качестве ингибиторов jak3 киназы
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020063854A (ko) 1999-09-17 2002-08-05 애보트 게엠베하 운트 콤파니 카게 치료제로서의 키나제 억제제
CA2598076A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
EP1874772A1 (en) 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2007035873A1 (en) 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689637A (zh) * 2018-09-13 2021-04-20 橘生药品工业株式会社 咪唑并吡啶酮化合物
CN112689637B (zh) * 2018-09-13 2023-11-10 橘生药品工业株式会社 咪唑并吡啶酮化合物
WO2021104277A1 (zh) * 2019-11-25 2021-06-03 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物
CN114728969A (zh) * 2019-11-25 2022-07-08 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物
RU2796163C1 (ru) * 2019-11-25 2023-05-17 Цзай Лаб (Шанхай) Ко., Лтд Пиримидоимидазольные соединения, применяемые в качестве ингибиторов днк-pk
CN114728969B (zh) * 2019-11-25 2024-03-08 再鼎医药(上海)有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物

Also Published As

Publication number Publication date
WO2008143674A1 (en) 2008-11-27
EP2152708A1 (en) 2010-02-17
MX2009012612A (es) 2009-12-07
JP2010527999A (ja) 2010-08-19
CA2686485A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
CN101679412A (zh) 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
EP3448838B1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
US8815906B2 (en) Tyrosine kinase inhibitors
CN101657453B (zh) 作为PKC-θ抑制剂的嘌呤类
CN101827848B (zh) 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
US10604514B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
EP3931188B1 (en) New isoindolinone substituted indoles and derivatives as ras inhibitors
DK2170340T3 (en) Methods and compositions for Stimulating neurogenesis and inhibition of neuronal degeneration BY USING ISOTHIAZOLOPYRIMIDINONER
CN102076691A (zh) 蛋白激酶抑制剂
EP3312182A1 (en) Brk inhibitory compound
TW200927135A (en) Polo-like kinase inhibitors
JP2009542684A (ja) ピリジノニルｐｄｋ１阻害剤
TW201121966A (en) Fused heterocyclic compounds as orexin receptor modulators
US10413537B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
TW200908983A (en) Heterocyclic compounds and uses thereof
CN102076690A (zh) 蛋白激酶抑制剂
TW201733580A (zh) Ｔｒｋ抑制劑抵抗性的癌治療劑
CN104520291A (zh) 用于调节egfr活性的化合物和组合物
JP7099725B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP2012524076A (ja) プロテインキナーゼｃｋ２活性に関連する障害の治療方法
TW200946526A (en) Dual pharmacophores-PDE4-muscarinic antagonistics
JP2013530250A (ja) 二環式ピリミジン化合物
US9249147B2 (en) Tyrosine kinase inhibitors
WO2019049891A1 (ja) Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
AU2013211455B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20100324

C20 Patent right or utility model deemed to be abandoned or is abandoned